| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.02M | 55.81M | 49.13M | 39.12M | 36.64M | 44.65M |
| Gross Profit | 27.31M | 23.94M | 20.01M | 16.63M | 15.60M | 14.59M |
| EBITDA | 7.14M | 5.65M | 4.53M | 2.58M | 1.54M | -3.94M |
| Net Income | 4.38M | 3.18M | 2.16M | 1.47M | -479.00K | -4.67M |
Balance Sheet | ||||||
| Total Assets | 64.67M | 65.84M | 57.62M | 52.42M | 54.14M | 59.81M |
| Cash, Cash Equivalents and Short-Term Investments | 12.12M | 9.56M | 4.60M | 4.26M | 4.64M | 6.86M |
| Total Debt | 1.68M | 1.89M | 1.94M | 2.82M | 2.84M | 2.79M |
| Total Liabilities | 20.96M | 24.51M | 18.75M | 15.42M | 18.79M | 22.78M |
| Stockholders Equity | 43.71M | 41.33M | 38.88M | 37.00M | 35.34M | 37.03M |
Cash Flow | ||||||
| Free Cash Flow | 9.28M | 6.59M | 2.75M | 915.00K | -1.48M | 4.53M |
| Operating Cash Flow | 9.72M | 8.52M | 3.02M | 1.23M | -607.00K | 5.75M |
| Investing Cash Flow | -2.24M | -1.93M | -1.39M | -582.00K | -842.00K | -1.22M |
| Financing Cash Flow | -1.57M | -1.61M | -1.17M | -1.17M | -1.02M | -1.15M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £87.24M | 19.49 | 24.24% | ― | -2.86% | 1.97% | |
74 Outperform | £11.06M | 16.64 | 7.90% | ― | 3.41% | 393.71% | |
69 Neutral | £46.53M | 10.70 | 10.49% | 1.69% | 21.43% | 44.70% | |
68 Neutral | £11.50M | 14.60 | 5.08% | 2.02% | 10.26% | 44.92% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
45 Neutral | £4.69M | -0.38 | -64.32% | ― | -46.72% | -50.00% | |
45 Neutral | £4.55M | -8.93 | -8.06% | ― | 63.81% | 71.62% |
Synectics plc has secured a £1.8 million contract with Bus Eireann, Ireland’s leading transport provider, through its systems integration business, Ocular Integration. This five-year deal will see Synectics’ real-time cloud services deployed across Bus Eireann’s fleet, enhancing operational efficiency and evidence retrieval capabilities. The contract strengthens Ocular’s position in Ireland’s transport sector and reinforces the longstanding relationship with Bus Eireann, providing predictable revenue streams and showcasing Synectics’ ability to deliver market-leading solutions.
The most recent analyst rating on (GB:SNX) stock is a Buy with a £347.00 price target. To see the full list of analyst forecasts on Synectics stock, see the GB:SNX Stock Forecast page.
Synectics plc has announced a positive trading update for the fiscal year ending November 2025, with expected revenues of approximately £67 million and profit before tax of no less than £5.7 million. The company has seen growth through securing extensions and repeat orders, as well as completing a significant contract in South-East Asia. Synectics is focused on sustainable growth through investment in product development and operational capabilities, and recent contract wins in renewables and decarbonisation sectors indicate success in broadening its market reach. The company maintains a strong balance sheet and is confident in its strategic priorities and long-term value creation.
The most recent analyst rating on (GB:SNX) stock is a Buy with a £347.00 price target. To see the full list of analyst forecasts on Synectics stock, see the GB:SNX Stock Forecast page.
Synectics plc has secured its first contracts in the renewables and decarbonisation markets, marking a strategic expansion into the broader energy sector. The contracts involve supplying advanced surveillance solutions for a carbon capture project in the UK and an offshore wind project in the North Sea, highlighting Synectics’ commitment to supporting the transition to renewable energy and its expertise in delivering integrated systems for critical environments.
The most recent analyst rating on (GB:SNX) stock is a Buy with a £347.00 price target. To see the full list of analyst forecasts on Synectics stock, see the GB:SNX Stock Forecast page.
Synectics plc announced that Andrew Lockwood, a Non-Executive Director, purchased 6,664 ordinary shares at 300 pence each, increasing his total shareholding to 15,323 shares, representing 0.09% of the company’s issued share capital. This transaction reflects continued confidence in the company’s strategic direction and may positively influence stakeholder perception, reinforcing Synectics’ position in the security and surveillance industry.
The most recent analyst rating on (GB:SNX) stock is a Buy with a £347.00 price target. To see the full list of analyst forecasts on Synectics stock, see the GB:SNX Stock Forecast page.
Synectics plc announced that its HMRC Approved Employee Share Acquisition Plan (ESAP) has purchased 7,672 ordinary shares at £2.93875 per share for its participants, including two PDMRs, David Aindow and Clare Bryan-Wright. This transaction reflects Synectics’ commitment to employee investment in the company, potentially strengthening stakeholder confidence and aligning employee interests with corporate performance.
The most recent analyst rating on (GB:SNX) stock is a Buy with a £347.00 price target. To see the full list of analyst forecasts on Synectics stock, see the GB:SNX Stock Forecast page.
Synectics plc announced that CEO Amanda Larnder and Chief Strategy Officer David Aindow exercised options over a total of 82,000 ordinary shares under the company’s Performance Share Plan. Following the exercise, shares were issued net of tax liabilities, with Aindow selling his shares immediately. This move reflects the company’s ongoing commitment to aligning executive interests with shareholder value.
The most recent analyst rating on (GB:SNX) stock is a Buy with a £356.00 price target. To see the full list of analyst forecasts on Synectics stock, see the GB:SNX Stock Forecast page.
Synectics plc announced that its Employee Share Acquisition Plan (ESAP) reinvested the company’s interim dividend to purchase 795 ordinary shares. This transaction resulted in PDMRs, including Business Strategy Director David Aindow and Group Director of HR Clare Bryan-Wright, acquiring additional shares, reflecting their ongoing commitment to the company’s growth and stability.
The most recent analyst rating on (GB:SNX) stock is a Buy with a £356.00 price target. To see the full list of analyst forecasts on Synectics stock, see the GB:SNX Stock Forecast page.